Kempharm, inc (KMPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-5,754

-6,037

3,063

-9,257

-12,291

-5,183

-15,071

-9,993

-26,219

-10,566

-9,981

-6,517

-16,322

-9,936

-13,414

9,768

-2,934

-9,203

-9,745

-29,742

-5,974

-11,840

-7,139

-3,571

-1,905

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-4,740

-

-

-

-

-

-

-

-

Write-off of deferred offering costs

-

106

0

0

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

1,029

746

1,057

1,317

1,290

1,250

2,586

1,378

1,281

1,150

1,158

1,165

1,089

1,042

3,279

1,257

1,022

913

492

873

91

45

52

91

26

Non-cash interest expense

1,244

-

-

-

863

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

1,164

1,031

1,186

-1,184

1,189

1,031

614

-835

1,475

968

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

632

-

-

704

96

Amortization of debt issuance costs and debt discount

571

675

371

305

305

512

326

390

390

390

391

390

390

391

390

393

442

475

480

477

477

478

477

159

0

Depreciation and amortization expense

72

75

76

75

78

79

79

83

83

85

87

84

80

78

42

29

26

23

21

20

20

19

18

19

19

Fair value adjustment related to derivative and warrant liability

-75

-215

-1,351

21

-453

-5,687

-4,468

-5,562

9,741

710

-1,312

-3,523

7,216

-2,723

1,299

-20,763

-10,278

764

2,089

22,661

1,762

3,221

2,190

1,570

242

Change in estimated deferred offering costs

-

106

0

0

10

-

-

-

-

-

-

-

-

0

0

0

445

-

-

-

-

-

-

-

-

Loss on sublease and disposal of property and equipment

200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in assets and liabilities:
Accounts and other receivables

400

-

-

-

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-455

876

-686

-528

-206

-412

-70

-620

1,650

203

572

-55

206

-219

133

440

-2,372

652

1,552

-1,006

30

-1,059

575

7

-46

Operating lease right-of-use assets

-86

-112

-69

-67

1,785

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

586

2,284

-3,674

-1,372

-1,027

-7,415

1,717

2,795

1,268

274

1,243

549

-2,867

734

1,077

-14

-679

562

2,928

-1,198

-977

-383

727

1

588

Operating lease liabilities

-48

-160

-97

-95

2,537

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

12

-10

0

-9

-779

-16

-35

-27

-24

-24

0

33

68

130

22

21

11

-

-

-

-

-

-

-

-

Net cash used in operating activities

-2,022

-3,098

-2,229

-7,344

-11,066

-14,998

-15,954

-9,152

-14,099

-6,936

-10,170

-6,473

-9,521

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,274

-3,865

-

-4,611

-5,255

-3,999

-6,963

-3,886

-2,934

-888

Purchases of property and equipment

11

5

4

0

17

-

-

-

-

3

35

44

99

89

335

153

66

40

55

19

21

28

8

7

4

Purchases of marketable securities and long-term investments

-

-

-

-

-

-

-

-

-

6,033

423

9,252

11,670

15,010

9,212

50,961

14,666

-

-

-

-

-

-

-

-

Maturities of marketable securities

-

0

0

0

3,260

7,979

463

15,682

9,229

16,052

6,113

15,335

17,471

20,838

13,162

10,645

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-11

-5

-4

0

3,243

7,964

457

15,682

9,229

10,016

5,655

6,039

5,702

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from equity line of credit

1,112

0

1,496

1,229

2,721

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of obligations under capital lease

-

-

-

-

-

51

48

45

49

38

42

40

37

29

35

7

8

8

9

7

8

7

8

8

8

Proceeds from at-the-market offering, net of commissions

-

-

-

-

-

-

-

1,194

2,798

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt and stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

310

0

90

583

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

150

13

Repayment of principal on finance lease liabilities

58

50

53

53

51

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-40,469

-14,732

-

-55

-19

-21

-30

-6

-7

-4

Proceeds from issuance of debt, net of discounts and commissions

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

82,800

-

-

-

-

-

-

-

-

Repayment of term notes and related accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

18,621

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

0

0

24

26

124

40

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

117

24

-

-

-

-

-

-

-

-

Net cash provided by financing activities

1,020

-350

1,443

1,176

2,670

23,265

788

1,217

2,749

-38

-42

-60

-63

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-1,013

-3,453

-790

-6,168

-5,153

16,231

-14,709

7,747

-2,121

3,042

-4,557

-494

-3,882

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of line of credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

33

1

1

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

63,612

-

-548

59,228

4,034

-1,774

-41

24,841

-22

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-48,723

45,015

-

-5,214

53,954

14

-8,767

-3,933

21,900

-914

Supplemental cash flow information:
Cash paid for interest

52

760

2,147

168

2,287

259

2,417

245

2,618

245

2,615

240

2,617

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

123

-

0

0

105

-

-

-

-

-

-

-

-

-235

320

0

0

-

-

-

-

-

-

-

-

Trade date receivables

-

-

-

-

-

-

-

-

1,511

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid offering costs charged to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

309

464

942

1,428

442

-

-

-

-

Commitment shares issued in connection with equity line of credit included in deferred offering costs

121

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment financed under a lease agreement

-

-

-

-

-

-

-

-

-

0

0

54

230

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

182

-

-

-

-

2

0

0

1

Transfer of warrants to equity upon exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

673

82

-

-

-

-

-

-

-

-

Property and equipment included in accounts payable and accrued expenses

4

-

-

-

-

-

-

0

3

-

-

5

2

-40

271

38

12

-

-

-

-

-

-

-

-

The 2021 Notes Converted to Common Stock [Member]
2019 Notes principal converted to common stock

9,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-